Nogest (Nomegestrol Acetate)

Nomegestrol acetate, the active ingredient in Nogest, is a progestin (synthetic progestogen) presented as an oral tablet for oral use. It is employed for progestogen‑only oral contraception and for hormone replacement therapy to relieve menopausal symptoms in women.

GNH USA supplies Nogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. All batches are manufactured under EU GMP guidelines and undergo full release testing before shipment.

Nogest, a progestin, acts on the hormonal pathway to prevent pregnancy and to manage menopausal symptoms.

- Contraception: provides progestogen‑only oral contraception by suppressing ovulation and stabilizing the endometrium. - Menopausal symptom relief: alleviates vasomotor symptoms such as hot flashes as part of hormone replacement therapy. - Endometrial protection: induces a predictable endometrial pattern during hormone replacement therapy, reducing the risk of hyperplasia.

Adverse reactions to Nogest may vary in frequency and severity, and patients should be aware of both common and serious possibilities.

Common Side Effects: - Nausea: mild stomach upset that often resolves spontaneously. - Headache: transient tension‑type headache. - Breast tenderness: mild discomfort or swelling of breast tissue. - Irregular menstrual bleeding: spotting or changes in cycle length.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring urgent care. - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Liver dysfunction: elevated liver enzymes, jaundice, or hepatitis. - Depression or mood disorders: persistent low mood, anxiety, or suicidal thoughts.

Before prescribing Nogest, clinicians should evaluate patient history and monitor for potential risks.

- Assess thrombotic risk: review personal or family history of clotting disorders and consider alternative contraception if risk is high. - Monitor liver function: obtain baseline liver enzyme levels and repeat testing periodically during treatment. - Evaluate blood pressure: measure blood pressure before initiating therapy and monitor regularly for hypertension. - Contraindicated in pregnancy: avoid use in women who are pregnant or may become pregnant; discuss effective backup methods. - Store at ambient temperature: keep tablets in the original container, protect from moisture and excessive heat, and discard after the expiration date.

Nogest can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Combined estrogen products: using additional estrogen‑containing drugs may increase thrombotic risk. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce plasma levels of nomegestrol acetate, decreasing efficacy. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise drug concentrations and heighten side‑effect risk.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): progestins can affect coagulation parameters; monitor INR closely. - Antidiabetic agents: hormonal changes may affect glucose control; check blood sugar regularly. - Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency; observe for abnormal uterine bleeding.